Skip to main content

Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro.

Publication ,  Journal Article
Varallo, VM; Gan, BS; Seney, S; Ross, DC; Roth, JH; Richards, RS; McFarlane, RM; Alman, B; Howard, JC
Published in: Oncogene
June 12, 2003

Dupuytren's disease (DD) is a superficial fibromatosis of the hand. Although the molecular mechanisms responsible for this disease are unknown, recent studies suggest that beta-catenin may be a key factor involved in fibromatosis. In this study, we analysed the in vivo and in vitro expression levels of beta-catenin in DD, using surgical specimens and primary cell lines. Although no somatic mutations (exon 3) of beta-catenin were detected, Western blot analysis revealed high levels of beta-catenin in diseased palmar fascia, and low to undetectable levels of beta-catenin in patient-matched normal palmar fascia. Immunohistochemistry analysis showed high levels of beta-catenin expression within the disease fascia, as well as cytoplasmic and nuclear accumulations of the protein. Immunoprecipitation of beta-catenin from seven patient lesions showed the protein to be tyrosine phosphorylated. Lastly, Western analysis of three patient-matched (disease and normal fascia) primary cell cultures showed significantly elevated levels of beta-catenin in disease cells cultured in three-dimensional collagen lattices. This is the first extensive in vivo and in vitro characterization of beta-catenin in DD, and the first to suggest that the extracellular matrix may play an important role in modulating beta-catenin stability in DD.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oncogene

DOI

ISSN

0950-9232

Publication Date

June 12, 2003

Volume

22

Issue

24

Start / End Page

3680 / 3684

Location

England

Related Subject Headings

  • beta Catenin
  • Tyrosine
  • Trans-Activators
  • Phosphorylation
  • Oncology & Carcinogenesis
  • Mutation
  • Immunohistochemistry
  • Humans
  • Extracellular Matrix
  • Dupuytren Contracture
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Varallo, V. M., Gan, B. S., Seney, S., Ross, D. C., Roth, J. H., Richards, R. S., … Howard, J. C. (2003). Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene, 22(24), 3680–3684. https://doi.org/10.1038/sj.onc.1206415
Varallo, Vincenzo M., Bing Siang Gan, Shannon Seney, Douglas C. Ross, James H. Roth, Robert S. Richards, Robert M. McFarlane, Benjamin Alman, and Jeffrey C. Howard. “Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro.Oncogene 22, no. 24 (June 12, 2003): 3680–84. https://doi.org/10.1038/sj.onc.1206415.
Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richards RS, et al. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene. 2003 Jun 12;22(24):3680–4.
Varallo, Vincenzo M., et al. “Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro.Oncogene, vol. 22, no. 24, June 2003, pp. 3680–84. Pubmed, doi:10.1038/sj.onc.1206415.
Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richards RS, McFarlane RM, Alman B, Howard JC. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene. 2003 Jun 12;22(24):3680–3684.

Published In

Oncogene

DOI

ISSN

0950-9232

Publication Date

June 12, 2003

Volume

22

Issue

24

Start / End Page

3680 / 3684

Location

England

Related Subject Headings

  • beta Catenin
  • Tyrosine
  • Trans-Activators
  • Phosphorylation
  • Oncology & Carcinogenesis
  • Mutation
  • Immunohistochemistry
  • Humans
  • Extracellular Matrix
  • Dupuytren Contracture